Potential prognostic value of PD-L1 and FOXP3 as predictors of relapse in breast cancer

Background: Expression of PD-L1 detected by immunohistochemistry can represent a new hope for cancer management. The role of PD L1 in breast cancer is still unclear. Similarly, is the role of tumor-infiltrating FOXP3 +ve regulatory T (Treg) cells where literature data are conflicting. Our study aimed to evaluate the immunohistochemical expression of PD L1 and FOXP3 in breast cancer, correlate them with clinicopathological parameters as well as evaluating their relation.Methods: This is a retrospective study carried out on 136 breast cancer specimens. Only cases with proved pathological diagnosis of infiltrating duct carcinoma of no special type (NST) were included. Tissue microarray blocks were constructed and immunostained with the polyclonal antibody for PDL1 and monoclonal antibody for FOXP3.Results: Statistically significant correlation was found between high FOXP3 and nearly all adverse prognostic factors including; grade III tumors (p = .003), basal-like subtype(p = .001), high Ki67(p = .001), negative ER status(p = .001), negative PR(p = .028), HER2 expression(p = .04), advanced stage (p = .001), and LN metastases(p = .001). For PDL1, only statistically significant correlation with high Ki67 (p = .018) and advanced stage(p = .03) was found. A statistically significant positive correlation was found between PD L1 and FOXP3(p= .001). No statistically significant correlation was found between both PDL1 and FOXP3 in relation to disease-free survival (DFS) (p = .054). PDL1, age (≥ 50 years), nodal metastases were significant predictors of relapse in breast cancer.Conclusion: The current study supports PDL1 as a predictor of relapse in breast cancer. Additionally, it highlights the synergistic role between PDL1 and FOXP3 in breast cancer microenvironment. Each can be considered as a poor prognostic marker in breast cancer. This raises a concern about the benefit of breast cancer patients from blocking of PDL1 pathway.

[1]  P. Fasching,et al.  Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study. , 2019, European journal of cancer.

[2]  K. Okoń,et al.  The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status , 2019, Virchows Archiv.

[3]  Jun Jiang,et al.  Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer , 2019, Medicine.

[4]  Yan Wang,et al.  Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting , 2019, Cancer biology & therapy.

[5]  Yang Wu,et al.  Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma , 2018, Medicine.

[6]  X. Ren,et al.  PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer , 2018, Cancer biology & therapy.

[7]  Qiaohong Wang,et al.  Prognostic value of tumor PD‐L1 expression combined with CD8+ tumor infiltrating lymphocytes in high grade serous ovarian cancer , 2017, International immunopharmacology.

[8]  P. Tan,et al.  Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer , 2017, Breast Cancer Research and Treatment.

[9]  M. Disis,et al.  Clinical significance of tumor-infiltrating lymphocytes in breast cancer , 2016, Journal of Immunotherapy for Cancer.

[10]  J. Madore,et al.  Programmed death ligand 1 expression in triple‐negative breast cancer is associated with tumour‐infiltrating lymphocytes and improved outcome , 2016, Histopathology.

[11]  Shuai Li,et al.  PD-L1 Expression Is Associated with Tumor FOXP3+ Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient , 2016, Journal of Cancer.

[12]  F. Bertucci,et al.  The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers , 2016, Oncoimmunology.

[13]  J. Joo,et al.  Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. , 2016, Clinical breast cancer.

[14]  L. Sarian,et al.  Prognostic significance of PD-L1 and PD-L2 in breast cancer. , 2016, Human pathology.

[15]  C. Caldas,et al.  PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Yong Song,et al.  PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. , 2015, Translational lung cancer research.

[17]  Jingting Jiang,et al.  B7-H1 expression associates with tumor invasion and predicts patient's survival in human esophageal cancer. , 2014, International journal of clinical and experimental pathology.

[18]  F. Gao,et al.  Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer , 2014, Breast Cancer Research and Treatment.

[19]  Vamsidhar Velcheti,et al.  In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas , 2014, Clinical Cancer Research.

[20]  O. Woo,et al.  Tumor-infiltrating Lymphocytes, Tumor Characteristics, and Recurrence in Patients With Early Breast Cancer , 2013, American journal of clinical oncology.

[21]  K. Shirouzu,et al.  FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis , 2013, Molecular and clinical oncology.

[22]  C. Drake,et al.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. , 2012, Current opinion in immunology.

[23]  D. Yin,et al.  CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes , 2011, Breast Cancer Research and Treatment.

[24]  J. Cheville,et al.  Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma , 2011, Clinical Cancer Research.